Lundbeck Tops Corporate Reputation Rankings for Fourth Consecutive Year

Annual survey finds Lundbeck US is first among leading pharmaceutical
companies in the eyes of patient groups.

DEERFIELD, Ill.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/corporatereputation?src=hash" target="_blank"gt;#corporatereputationlt;/agt;–For the fourth straight year, patient groups ranked Lundbeck US, an
affiliate of the global pharmaceutical company H. Lundbeck A/S, #1 for
corporate reputation. According to the new PatientView Corporate
Reputation of Pharma, USA Edition, which is based on a survey of
U.S. patient groups, Lundbeck has the best overall corporate reputation
among 30 leading pharmaceutical companies.

“To be ranked #1 four years in a row is an incredible honor and a
testament to our employees’ unwavering commitment to the patient
communities we serve,” said Peter Anastasiou, executive vice president
and head of Lundbeck North America. “As the only global pharmaceutical
company solely focused on brain health, we feel an intense
responsibility to people impacted by brain diseases. Patient-centricity
isn’t a passive corporate value; it is at the core of who we are, it is
embedded in our company purpose and it motivates every individual at
Lundbeck.”

Report highlights

The PatientView report compiles feedback on the performance of
pharmaceutical companies on key indicators of corporate reputation. In
addition to the overall top ranking, Lundbeck also ranked first in 10
individual categories, as judged by patient groups familiar with the
company. These include:

• Patient-centricity
• Patient information
• Patient safety
• High-quality products
• Transparency in pricing
• Transparency in clinical data
• Transparency in funding
• Corporate integrity
• Quality of patient-group relationships
• “Beyond the pill” services

Patient groups that work directly with Lundbeck gave the company
especially high marks.

• 60 percent ranked Lundbeck #1 on quality of relationships
• 50 percent ranked Lundbeck first for “beyond-the-pill” services
• 46.7 percent identified the company as having the “most effective
  patient-centered strategy”
• 46.7 percent identified the company as having the “most integrity”

Lundbeck’s patient-centricity

In 2018, Lundbeck partnered with 27 different patient groups, and the
company’s approximately 750 U.S. employees participated in more than 600
patient advocacy events across the country. “Patient advocacy is
embedded into our culture and our employees embrace the opportunity to
engage with patient communities,” Anastasiou said. “We also regularly
engage with patient groups in more organized ways, convening
representatives of patient communities to help us understand gaps in
treatment and the functional outcomes that matter most to patients.”

One example of the company’s close collaboration with patient groups was
the highly successful 2018 launch of “Sidekicks™:
Uniting Youth and People with Parkinson’s.” This unique
intergenerational program, developed in partnership with the Davis
Phinney Foundation and in collaboration with leading Parkinson’s patient
and research organizations, brings together adults with Parkinson’s and
school-aged youth in a series of interactive art and story-sharing
workshops. Because Parkinson’s can impact the activities of daily
living, some people may develop a feeling of isolation if they are
spending less time with friends and loved ones. Sidekicks helps people
with Parkinson’s share their experiences while fostering positive,
meaningful connections with youth. In 2018, Sidekicks brought together
100 youth and people with Parkinson’s across five pilot programs. The
program was so well received, it is expanding to 10 markets this year.

“Lundbeck is a true leader in collaborating with advocacy
organizations,” said Polly Dawkins, executive director of the Davis
Phinney Foundation. “They listen and deeply respect the needs of the
Parkinson’s community, and then they help to advance innovative
programs. We are proud to call them a partner.”

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical
company specialized in brain diseases. For more than 70 years, we have
been at the forefront of neuroscience research. We are tirelessly
dedicated to restoring brain health, so every person can be their best.

Our approximately 5,000 employees in more than 50 countries are engaged
in the entire value chain throughout research, development, production,
marketing and sales. Our pipeline consists of several late-stage
development programs and our products are available in more than 100
countries. Our research center is based in Denmark and our production
facilities are located in Denmark, France and Italy.

In the U.S., Lundbeck employs approximately 750 people focused solely on
accelerating therapies for brain disorders. With a special commitment to
the lives of patients, families and caregivers, Lundbeck US actively
engages in a broad range of initiatives each year that support our
patient communities. For additional information, we encourage you to
visit at www.lundbeckus.com,
subscribe to our newsletter at Newsroom.LundbeckUS.com
and connect with us on Twitter at @LundbeckUS.

Contacts

Lundbeck Media Contact:
Molly Brennan
Senior Manager,
Corporate Communications
[email protected]